Vineet Labs Approves Rights Issue of 99.87 Lakh Shares Worth ₹29.96 Crore
Vineet Laboratories Limited's Rights Issue Committee approved a Rights Issue of 99,87,258 equity shares at ₹30 each, aggregating ₹29.96 crore. The issue opens on January 1, 2026, and closes on January 21, 2026. The record date is December 23, 2025.
The rights issue will increase the equity base and potentially fund business expansion, which could have a medium-term impact on the company's financial performance and stock.
The company is raising capital through a rights issue, which is generally seen as a positive step for growth and expansion.
Vineet Laboratories Limited announced that its Rights Issue Committee of the Board of Directors, in a meeting held on December 17, 2025, approved key aspects of a Rights Issue.
The company plans to issue 99,87,258 fully paid-up Equity Shares, each with a face value of ₹10, at a price of ₹30 per share. This includes a premium of ₹20 per share. The total issue size, assuming full subscription, amounts to ₹29,96,17,740 (₹29.96 crore).
The full issue price of ₹30 per share will be payable upon application. The Rights Issue is structured with an opening date of January 1, 2026, and a closing date of January 21, 2026. Key dates for renunciation include January 16, 2026 (Last date of On-Market Renunciation) and January 20, 2026 (Last date of Off-Market Renunciation). The record date for determining eligible equity shareholders entitled to receive rights entitlements is December 23, 2025.
The Rights Entitlement Ratio is set at 13 Rights Equity Shares for every 12 Equity Shares held as of the record date. Prior to the issue, the company has 92,19,008 equity shares outstanding, which are expected to increase to 1,92,06,266 equity shares post the Rights Issue, assuming full subscription.
The committee also adopted the Letter of Offer, which will be filed with the BSE, NSE, and SEBI, and subsequently dispatched to eligible shareholders. The Rights Issue Committee meeting commenced at 2:00 PM and concluded at 3:00 PM.
What to do with a filing like this
Vineet Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under rights issue. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Vineet Laboratories Limited. Read the original for the full detail.